← All drugs Report issue

ono-7579

Small moleculeexperimental

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

1

Phase 3

0

Phase 4

0

Earliest trial started Jun 30, 2017 (NCT03182257)

Timeline

2010s

Jan 1, 2017
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Neoplasms · Phase 1/Phase 2

Mechanism of action

NT-3 growth factor receptorINHIBITOR
NTRK3 inhibitor
- NT-3 growth factor receptor (NTRK3) ↗
Neurotrophic tyrosine kinase receptor type 2INHIBITOR
NTRK2 inhibitor
- BDNF/NT-3 growth factors receptor (NTRK2) ↗
Nerve growth factor receptor Trk-AINHIBITOR
NTRK1 inhibitor
- High affinity nerve growth factor receptor (NTRK1) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CS(=O)(=O)c1ccc(C(F)(F)F)cc1NC(=O)Nc1cnc(Oc2ccc(-c3cc(Cl)cnc3N)cc2)nc1

Mol. weight: 578.96 g/mol
Lipinski Ro5: 2 violation(s)
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL3892052 ↗

Also known as

ono-7579

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT03182257	Phase 1/Phase 2 (Phase 2)	Jun 30, 2017	Ono Pharmaceuticals

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Ono Pharmaceuticals	For profit	1	1	1	2017

1 organizations

Page 1 / 1